MX2011008261A - FORMULACIONES FARMACEUTICAS DE PEPTIDOS INHIBIDORES DE TGF-ß1. - Google Patents
FORMULACIONES FARMACEUTICAS DE PEPTIDOS INHIBIDORES DE TGF-ß1.Info
- Publication number
- MX2011008261A MX2011008261A MX2011008261A MX2011008261A MX2011008261A MX 2011008261 A MX2011008261 A MX 2011008261A MX 2011008261 A MX2011008261 A MX 2011008261A MX 2011008261 A MX2011008261 A MX 2011008261A MX 2011008261 A MX2011008261 A MX 2011008261A
- Authority
- MX
- Mexico
- Prior art keywords
- tgf
- pharmaceutical compositions
- inhibitor peptides
- relates
- emulsion
- Prior art date
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Nanotechnology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Neurology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Dispersion Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Transplantation (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a un complejo que comprende un péptido inhibidor de TGF-ß1 y una ciclodextrina o un derivado de la misma. También se proporciona una emulsión de un péptido inhibidor de TGF-ß1 que comprende cetil PEG/PPG-10/1 dimeticona. Se describen procedimientos para la preparación de dicho complejo y dicha emulsión, así como su uso para la fabricación de un medicamento para el tratamiento de una enfermedad o estado patológico mediado por TGF-ß1.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES200900319 | 2009-02-05 | ||
PCT/ES2010/070062 WO2010089443A2 (es) | 2009-02-05 | 2010-02-04 | FORMULACIONES FARMACÉUTICAS DE PÉPTIDOS INHIBIDORES DE TGF- β1 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2011008261A true MX2011008261A (es) | 2011-09-01 |
Family
ID=42320987
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2011008261A MX2011008261A (es) | 2009-02-05 | 2010-02-04 | FORMULACIONES FARMACEUTICAS DE PEPTIDOS INHIBIDORES DE TGF-ß1. |
Country Status (10)
Country | Link |
---|---|
US (1) | US20110294734A1 (es) |
EP (1) | EP2394666A2 (es) |
JP (1) | JP2012516879A (es) |
CN (1) | CN102307598A (es) |
AU (1) | AU2010210033A1 (es) |
BR (1) | BRPI1008815A2 (es) |
CA (1) | CA2750559A1 (es) |
MX (1) | MX2011008261A (es) |
RU (1) | RU2011136694A (es) |
WO (1) | WO2010089443A2 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012154567A2 (en) * | 2011-05-06 | 2012-11-15 | Albert Einstein College Of Medicine Of Yeshiva University | Human invasion signature for prognosis of metastatic risk |
EP2914277B1 (en) * | 2012-11-02 | 2017-09-13 | Celgene Corporation | Activin-actrii antagonists and uses for treating bone and other disorders |
EP2994156A4 (en) * | 2013-05-10 | 2017-01-11 | Southern Research Institute | Compounds, compositions and methods for the treatment of diseases through inhibiting tgf- activity |
MA41052A (fr) | 2014-10-09 | 2017-08-15 | Celgene Corp | Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii |
MD4801C1 (ro) | 2014-12-03 | 2022-10-31 | Celgene Corporation | Antagonişti ai activin-ActRII şi utilizarea lor pentru tratamentul sindroamelor mielodisplazice |
KR101841748B1 (ko) * | 2016-02-18 | 2018-05-08 | (주)케어젠 | 멜라닌 생성 촉진 활성을 나타내는 펩타이드 및 이의 용도 |
WO2019234221A1 (en) | 2018-06-08 | 2019-12-12 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for stratification and treatment of a patient suffering from chronic lymphocytic leukemia |
CN110483648A (zh) * | 2019-08-27 | 2019-11-22 | 南京安吉生物科技有限公司 | 一种融合多肽及其应用 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5997856A (en) * | 1988-10-05 | 1999-12-07 | Chiron Corporation | Method and compositions for solubilization and stabilization of polypeptides, especially proteins |
US5215520A (en) * | 1991-09-17 | 1993-06-01 | Centre Internationale De Recherches Dermatologiques Galderma (C.I.R.D. Galderma) | Method for delivering an active substance topically or percutaneously |
US6132739A (en) * | 1998-09-01 | 2000-10-17 | Amway Corporation | Makeup compositions and methods of making same |
ES2146552B1 (es) | 1998-11-24 | 2001-04-16 | Inst Cientifico Tecnol Navarra | Peptidos inhibidores de tgf/31 |
ES2371026T3 (es) * | 2001-10-19 | 2011-12-26 | Atritech, Inc. | Dispositivo de oclusión ajustable en la orejuela auricular izquierda. |
US7244573B2 (en) | 2001-12-03 | 2007-07-17 | Bristol-Myers Squibb Company | Polynucleotides and polypeptides associated with the development of rheumatoid arthritis |
ITRM20020119A1 (it) * | 2002-03-05 | 2003-09-05 | Geymonat Spa | Composizioni contenenti plgf ad uso farmaceutico e cosmetico. |
ES2304069B1 (es) * | 2003-08-22 | 2009-08-12 | Proyecto De Biomedicina Cima, S.L. | Peptidos con capacidad de unirse al factor transformante de crecimiento beta 1 (tgf-b1). |
US7279503B1 (en) * | 2004-11-02 | 2007-10-09 | Siltech Llc | Water in oil emulsions |
CA2627298A1 (en) * | 2005-10-24 | 2007-05-03 | Proyecto De Biomedicina Cima, S.L. | Use of tgf-.beta.1 inhibitor peptides in the preparation of an immune response modulating agent |
US7582609B2 (en) * | 2006-03-01 | 2009-09-01 | Digna Biotech, S.L. | Method for the treatment of skin fibrosis and suitable compositions for such treatment |
DE102006031500A1 (de) * | 2006-07-06 | 2008-04-17 | Henkel Kgaa | O/W-Emulsion |
WO2008013928A2 (en) * | 2006-07-28 | 2008-01-31 | Biogen Idec Ma Inc. | Treatment of cancer with interferon gene delivery in combination with a tgf-beta inhibitor |
SG179457A1 (en) * | 2006-12-01 | 2012-04-27 | Anterios Inc | Peptide nanoparticles and uses therefor |
-
2010
- 2010-02-04 MX MX2011008261A patent/MX2011008261A/es not_active Application Discontinuation
- 2010-02-04 CA CA2750559A patent/CA2750559A1/en not_active Abandoned
- 2010-02-04 CN CN2010800067872A patent/CN102307598A/zh active Pending
- 2010-02-04 EP EP10708231A patent/EP2394666A2/en not_active Withdrawn
- 2010-02-04 US US13/147,145 patent/US20110294734A1/en not_active Abandoned
- 2010-02-04 BR BRPI1008815-6A patent/BRPI1008815A2/pt not_active IP Right Cessation
- 2010-02-04 RU RU2011136694/15A patent/RU2011136694A/ru not_active Application Discontinuation
- 2010-02-04 AU AU2010210033A patent/AU2010210033A1/en not_active Abandoned
- 2010-02-04 JP JP2011548731A patent/JP2012516879A/ja active Pending
- 2010-02-04 WO PCT/ES2010/070062 patent/WO2010089443A2/es active Application Filing
Also Published As
Publication number | Publication date |
---|---|
US20110294734A1 (en) | 2011-12-01 |
EP2394666A2 (en) | 2011-12-14 |
AU2010210033A1 (en) | 2011-08-04 |
CA2750559A1 (en) | 2010-08-12 |
CN102307598A (zh) | 2012-01-04 |
WO2010089443A2 (es) | 2010-08-12 |
JP2012516879A (ja) | 2012-07-26 |
WO2010089443A3 (es) | 2010-10-21 |
RU2011136694A (ru) | 2013-03-10 |
BRPI1008815A2 (pt) | 2018-02-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2011008261A (es) | FORMULACIONES FARMACEUTICAS DE PEPTIDOS INHIBIDORES DE TGF-ß1. | |
AU2018201997B2 (en) | Peptides which inhibit activated receptors and their use in cosmetic or pharmaceutical compositions | |
CY1123901T1 (el) | Φαρμακευτικη συνθεση και χορηγησεις αυτης | |
EA201190217A1 (ru) | Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение | |
PH12013502192A1 (en) | Antibodies against human angiopoietin 2 | |
PH12016500040A1 (en) | Pcsk9 vaccine | |
WO2014127917A8 (en) | Combination of vaccination and inhibition of the pd-1 pathway | |
EA201290498A1 (ru) | Терапевтические полимерные наночастицы, включающие эпотилон, и способы их получения и применения | |
WO2012080729A3 (en) | Casein kinase 1delta (ck1delta) inhibitors and their use in the treatment of neurodegenerative diseases such as tauopathies | |
UA94734C2 (ru) | ТЕРАПЕВТИЧЕСКОЕ АНТИТЕЛО, КОТОРОЕ СВЯЗЫВАЕТСЯ С b-АМИЛОИДНЫМ ПЕПТИДОМ | |
WO2009072610A1 (ja) | 癌ワクチン組成物 | |
IN2012DN02736A (es) | ||
EA200970287A1 (ru) | Способы, соединения, композиции и носители, подходящие для доставки 3-амино-1-пропансульфоновой кислоты | |
WO2013061004A8 (fr) | Nouveaux composés di-substitués de la diamino-3,4-cyclobutène-3-dione-1,2 utiles dans le traitement de pathologies médiées par des chimiokines | |
WO2007002666A3 (en) | Pharmaceutical and therapeutic compostions derived from garcinia mangostana l plant | |
MX367131B (es) | Sales de xantilio 3,6-disustituidas. | |
MX2009012922A (es) | Vacunacion intradermica de un peptido del virus del papiloma humano. | |
UA117154C2 (uk) | Антагоністи s1p3 | |
TN2012000431A1 (en) | Composition comprising the amyloid beta 1-6 peptide coupled to a virus-like particle and an adjuvant | |
CY1110401T1 (el) | Παραγωγα των 1-φαινυλαλκανοκαρβοξυλικων οξεων για την αντιμετωπιση των νευροεκφυλιστικων νοσων | |
IN2011KN05169A (es) | ||
GB2473579A (en) | Stat3 and TYK2 as drug targets for neurodegenerative diseases | |
MX2012002631A (es) | Capsulas con aroma. | |
WO2014141169A3 (en) | Novel anti-neurodegenerative natural compounds isolated from alpiniae oxyphyllae fructus and total synthesis theirof | |
MX350145B (es) | Extracto proteolitico a partir de bromelaina para el tratamiento de trastornos del tejido conectivo. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |